Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 23 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $492.57, which forecasts a 7.72% increase in the stock price over the next year. The lowest target is $411 and the highest is $575.

Price Target: $492.57 (+7.72%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$411	$492.57	$485	$575
Change	-10.12%	+7.72%	+6.07%	+25.75%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	8	8	8	8	8	8
Buy	6	6	8	8	8	9
Hold	11	10	9	10	10	9
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	25	24	25	26	26	26

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Terence Flynn Morgan Stanley	Morgan Stanley	Hold → Buy Upgrades $438 → $516	Hold → Buy	Upgrades	$438 → $516	+12.85%	Dec 3, 2025
Colin Bristow UBS	UBS	Strong Buy Maintains $553 → $546	Strong Buy	Maintains	$553 → $546	+19.41%	Nov 7, 2025
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $423 → $415	Hold	Maintains	$423 → $415	-9.24%	Nov 4, 2025
Gena Wang Barclays	Barclays	Hold Maintains $408 → $414	Hold	Maintains	$408 → $414	-9.46%	Nov 4, 2025
Paul Matteis Stifel	Stifel	Hold Maintains $455 → $445	Hold	Maintains	$455 → $445	-2.68%	Nov 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.23B

Increased by 11.01%

from 11.02B

Revenue Next Year

13.30B

Increased by 8.74%

from 12.23B

EPS This Year

18.68

from -2.08

EPS Next Year

20.39

Increased by 9.12%

from 18.68

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.21B	7.57B	8.93B	9.87B	11.02B	12.23B	13.30B
Revenue Growth	49.08%	22.06%	17.91%	10.51%	11.66%	11.01%	8.74%
EPS	10.29	9.01	12.82	13.89	-2.08	18.68	20.39
EPS Growth	128.16%	-12.44%	42.29%	8.35%	-	-	9.12%
Forward PE	-	-	-	-	-	24.47	22.43
No. Analysts	-	-	-	-	-	35	33

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	12.8B	14.8B
Avg	12.2B	13.3B
Low	11.7B	11.8B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	16.4%	21.3%
Avg	11.0%	8.7%
Low	5.8%	-3.4%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	20.11	24.93
Avg	18.68	20.39
Low	15.29	17.79

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	33.4%
Avg	-	9.1%
Low	-	-4.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.